Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation

Inclusion Criteria: * Male or female patients ≥ 18 years of age * Histological diagnosis of HCC, whether new or recurrent following a prior curative therapeutic management \> 6 months. * Barcelona Clinical Liver Cancer(BCLC) stage Category A * Patients with HCC eligible for EP as assessed by multidisciplinary board corresponding to the following extension: * Uninodular HCC≥ 2 cm and ≤ 5 cm, no macroscopic vascular invasion * Multinodular HCC maximum 3 nodules ≤ 3 cm, no macroscopic vascular invasion * At least one uni-dimensional measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to modified RECIST for HCC * Liver function status Child-Pugh Class A * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2 * Adequate bone marrow, liver and renal function * Life expectancy ≥ 3 months * Women of childbearing potential and men must agree to use adequate contraception * Patients affiliated to a Social Security System * Written informed consent signed Exclusion Criteria: * Patients with contraindications to EP (Pacemakers or patients who have a history of cardiac arrhythmias or irregular heartbeats, ascites, Coagulopathy, Ongoing infection) * Patients with contraindication to contrast medium intravenous injection either gadolinium or iodinate * Prior liver transplantation or candidates for liver transplantation * Prior systemic treatment for HCC, in particular agents targeting T-cell costimulation or checkpoint pathways (including those targeting PD-1, PD-L1 or PD-L2, CD137, or cytotoxic T-lymphocyte antigen \[CTLA-4\]). * Patients with uncontrolled HBV infection and viral load above 100 IU/mL. * Patients with large esophageal varices at risk of bleeding that are not being treated with conventional medical intervention * Past or concurrent history of neoplasm other than HCC, except for in situ carcinoma of the cervix uteri and/or non-melanoma skin cancer and superficial bladder tumors. Any cancer curatively treated \> 3 years prior to study entry is permitted * Known history or symptomatic metastatic brain or meningeal tumors * Major surgical procedure or significant traumatic injury within 28 days before enrolment * Congestive heart failure New York Heart Association (NYHA) ≥ class 2 * Unstable angina or myocardial infarction within the past 6 months before enrolment * Grade 3 (severe) hypertension ≥180 and/or ≥110 mmHG (systolic and diastolic, according to National Heart Foundation 2016) * Patients with phaeochromocytoma * Refractory ascites according to EASL guidelines definition (ascites that cannot be mobilized or the early recurrence of which cannot be prevented because of a lack of response to sodium restriction and diuretic treatment) * Persistent proteinuria of NCI-CTCAE version 4.0 ≥ Grade 3 * Ongoing infection \> Grade 2 according to NCI-CTCAE version 4.0. Hepatitis B is allowed if no active replication is present (HBV replication below 100 IU/mL). Hepatitis C is allowed if no antiviral treatment is required * Clinically significant bleeding NCI-CTCAE version 4.0 ≥ Grade 3 within 30 days before enrolment * Arterial or venous thrombotic or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism within 6 months before enrolment * Any psychological, familial, sociological, geographical or illness or medical condition that could jeopardize the safety of the patient and/or his compliance with the study protocol and follow-up procedure * Known history of human immunodeficiency virus (HIV) infection * Seizure disorder requiring medication * Non-healing wound, ulcer or bone fracture * Known hypersensitivity to the study drug or excipients in the formulation * Any malabsorption condition * Breast feeding * Pregnancy